|11.80|| +0.05 / +0.43%|
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company which engages in research, discovery, development and commercialization of proprietary drugs in the Americas, Europe and Asia. It is developing prostones, which are ion channel activators, to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders, as well as other therapeutic applications of drug technologies. The company's product pipeline includes AMITIZA for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation. Its product pipeline also consists of Unoprostone Isopropyl, which is in Phase III trial for the treatment of retinitis pigmentosa and in pre-clinical stage for the treatment of geographic atrophy; and Cobiprostone that has completed Phase Ib trial for the treatment of oral mucositis, as well as in Phase II trial for the treatment of non-erosive reflux diseases. Sucampo Pharmaceuticals was founded by Dr. Ryuji Ueno and Dr. Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD.
|Peter S. Greenleaf||Chairman & Chief Executive Officer|
|Andrew P. Smith||Chief Financial Officer|
|Peter Lichtlen||Chief Medical Officer|
|Peter Alec Kiener||Chief Scientific Officer|
|Matthias A. Alder||Secretary, General Counsel & Executive VP|